<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065710</url>
  </required_header>
  <id_info>
    <org_study_id>ZL-1211-001</org_study_id>
    <nct_id>NCT05065710</nct_id>
  </id_info>
  <brief_title>A Study of ZL-1211 in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase I/II, First-in-Human, Open-Label, Dose Escalation Study of ZL- 1211 in Patients With Unresectable or Metastatic Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zai Biopharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zai Lab (Hong Kong), Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I/II, open-label, dose escalation, and cohort expansion study designed&#xD;
      to characterize the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD),&#xD;
      immunogenicity, and preliminary antitumor activity of ZL-1211 administered by IV infusion on&#xD;
      a every 2 weeks (Q2W) schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two stages, Phase I -Dose Escalation Phase to determine the maximum&#xD;
      tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211,&#xD;
      and Phase II -Cohort Expansion Phase to further define the safety and initial antitumor&#xD;
      activity of ZL-1211 with the dose established in the Dose Escalation Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">July 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase I, the Dose Escalation Phase of the study will enroll patients with locally advanced or metastatic solid tumors of any histology with positive CLDN18.2. Phase II, the Cohort Expansion Phase of the study, will be conducted after determination of the dose level (RP2D) for cohort expansion based on the results of Phase I to explore the preliminary efficacy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I ：MTD or MAD</measure>
    <time_frame>One month</time_frame>
    <description>To determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of ZL-1211</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I and Phase II: safety and tolerability</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Incidence of Treatment-Related Adverse Events as Assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: preliminary antitumor activity</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Objective response rate defined as the proportion of patients with partial response (PR) proportion of patients with partial response (PR) or complete response (CR) based on Investigator assessment of tumor lesions per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):AUC</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):Cmax</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Maximum serum concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):Tmax</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Time to reach Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):Ctrough</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):Vss</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Volume of distribution at steady state (Vss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):CL</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: pharmacokinetics (PK):t1/2</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: immunogenicity</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Incidence of anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and Phase II: immunogenicity</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Quantity of anti-drug antibodies (ADAs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: preliminary antitumor activity</measure>
    <time_frame>Approximately 10 months</time_frame>
    <description>Duration of response (DOR), defined as the time from the first date of objective response (CR or PR) to the first documented date of disease progression per RECIST v1.1 or the date of death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ZL-1211 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZL-1211</intervention_name>
    <description>Phase 1 dose escalation part will enroll about 12-42 patients, Phase 2 dose expansion part will enroll about 15-40 patients in each cohort</description>
    <arm_group_label>ZL-1211 monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients are eligible to be included in the study only if all the following inclusion&#xD;
        criteria apply:&#xD;
&#xD;
          1. Adults≥ 18 years of age.&#xD;
&#xD;
          2. Willing and able to provide signed and dated informed consent prior to any study&#xD;
             related procedures and willing and able to comply with all study procedures.&#xD;
&#xD;
          3. All patients from Phase I and Phase II are required to provide tumor tissue for&#xD;
             CLDN18.2 IHC assessment, and only patients with CLDN18.2-positive tumors will be&#xD;
             included in this study.&#xD;
&#xD;
          4. Patients with histologically or cytologically confirmed metastatic or locally advanced&#xD;
             solid tumors, refractory to standard treatment&#xD;
&#xD;
          5. Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          7. Adequate hepatic function&#xD;
&#xD;
               1. Total bilirubin ≤ 1.5 × upper limit of normal (ULN).&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN;&#xD;
                  AST or ALT ≤ 5 × ULN if liver metastases are present.&#xD;
&#xD;
          8. Adequate renal function, as defined by serum creatinine &lt; 1.5 × ULN OR calculated&#xD;
             creatinine CL &gt; 40 mL/min, Cockroft-Gault Equation:&#xD;
&#xD;
          9. Hematological function defined as:&#xD;
&#xD;
               1. Absolute neutrophil count ≥ 1.5 × 109/L without growth factor support in the 2&#xD;
                  weeks prior to screening.&#xD;
&#xD;
               2. Platelet count ≥ 100 × 109/L without transfusion in the 2 weeks prior to&#xD;
                  screening.&#xD;
&#xD;
               3. Hemoglobin ≥ 9 g/dL without transfusion in the 2 weeks prior to screening.&#xD;
&#xD;
         10. Prothrombin time, international normalized ratio or/and activated partial&#xD;
             thromboplastin time &lt; 1.5 × ULN.&#xD;
&#xD;
         11. Recovery, to Grade 0-1, from AEs related to prior anticancer therapy except alopecia,&#xD;
             &lt; Grade 2 sensory neuropathy, lymphopenia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with known human immunodeficiency virus (HIV) or acquired immunodeficiency&#xD;
             syndrome related illness or known active or chronic hepatitis B virus infection or&#xD;
             hepatitis C virus.&#xD;
&#xD;
          2. Any uncontrolled active infection.&#xD;
&#xD;
          3. Previous exposure to any CLDN18.2 antibody or CLDN18.2 chimeric antigen receptor T&#xD;
             cell therapy.&#xD;
&#xD;
          4. Newly diagnosed or symptomatic brain metastases anticonvulsants are allowed.&#xD;
&#xD;
          5. Severe cardiovascular disease; New York Heart Association Class II-IV heart failure&#xD;
             within 6 months of screening; uncontrolled arrhythmia within 6 months of screening.&#xD;
&#xD;
          6. Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is&#xD;
             shorter) prior to screening; palliative radiotherapy within 2 weeks prior to&#xD;
             screening.&#xD;
&#xD;
          7. Major surgery within 4 weeks prior to first dose; minor surgery within 2 weeks prior&#xD;
             to first dose.&#xD;
&#xD;
          8. Symptomatic intrinsic lung disease (chronic obstructive pulmonary disease, pulmonary&#xD;
             fibrosis).&#xD;
&#xD;
          9. Gastrointestinal abnormalities including:&#xD;
&#xD;
               1. Documented unresolved gastric outlet obstruction or persistent vomiting defined&#xD;
                  as ≥ 3 episodes within 24 hours.&#xD;
&#xD;
               2. Active peptic ulcer disease required treatment in the past 3 months.&#xD;
&#xD;
               3. Gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in&#xD;
                  the past 3 months without evidence of resolution documented by endoscopy or&#xD;
                  colonoscopy.&#xD;
&#xD;
               4. Documented active colitis within 4 weeks prior to study entry, including&#xD;
                  infectious colitis, radiation colitis and ischemic colitis.&#xD;
&#xD;
               5. History of ulcerative colitis or Crohn's disease.&#xD;
&#xD;
         10. Patient has received systemic immunosuppressive therapy, including systemic&#xD;
             corticosteroids 2 weeks prior to first dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zai Biopharmaceutical (Suzhou) Co., Ltd.</last_name>
    <phone>+862161632588</phone>
    <email>Study-ZL-1211-001@zailaboratory.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>2012</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sunil Sharma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>2014</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bert O'Neil</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>2011</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Spigel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>2013</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Chaudhry</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLDN18.2</keyword>
  <keyword>Solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

